NasdaqCM - Nasdaq Real Time Price USD

Accelerate Diagnostics, Inc. (AXDX)

0.9089 +0.0215 (+2.42%)
As of 12:41 PM EDT. Market Open.
Loading Chart for AXDX
DELL
  • Previous Close 0.8874
  • Open 0.9090
  • Bid 0.8681 x 100
  • Ask 0.9771 x 100
  • Day's Range 0.8888 - 0.9449
  • 52 Week Range 0.7300 - 11.9000
  • Volume 90,761
  • Avg. Volume 81,764
  • Market Cap (intraday) 19.691M
  • Beta (5Y Monthly) 0.53
  • PE Ratio (TTM) --
  • EPS (TTM) -4.9400
  • Earnings Date May 9, 2024 - May 13, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 1.50

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.

acceleratediagnostics.com

134

Full Time Employees

December 31

Fiscal Year Ends

Recent News: AXDX

Performance Overview: AXDX

Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

AXDX
76.81%
S&P 500
6.23%

1-Year Return

AXDX
86.83%
S&P 500
22.59%

3-Year Return

AXDX
98.87%
S&P 500
22.54%

5-Year Return

AXDX
99.50%
S&P 500
74.25%

Compare To: AXDX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: AXDX

Valuation Measures

Annual
As of 4/22/2024
  • Market Cap

    19.71M

  • Enterprise Value

    45.72M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.94

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    3.79

  • Enterprise Value/EBITDA

    -0.92

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -70.07%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    12.06M

  • Net Income Avi to Common (ttm)

    -61.62M

  • Diluted EPS (ttm)

    -4.9400

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    13.22M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -25.94M

Research Analysis: AXDX

Analyst Price Targets

1.50
1.50 Average
0.9089 Current
1.50 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

Company Insights: AXDX

Fair Value

0.9089 Current
 

Dividend Score

0 Low
AXDX
Sector Avg.
100 High
 

Hiring Score

0 Low
AXDX
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
AXDX
Sector Avg.
100 High
 

People Also Watch